Pazopanib Monotherapy Is Active in Relapsed and Refractory Metastatic Gastroesophageal Adenocarcinoma and Can Produce Durable Response
- 14 Downloads
Metastatic gastroesophageal adenocarcinomas (GEA) constitute a challenging treatment problem. Two-thirds of all patients will either present with or develop metastatic disease over the course of their therapy. Despite advances in treatment, the prognosis of metastatic GEA remains poor with a median survival of less than 1 year, except perhaps for HER2/neu-amplified patients who can achieve better outcomes with the integration of HER2-directed targeted therapy . The standard systemic therapy for metastatic GEA comprises palliative-intent chemotherapy, with multiple active agents given in several sequential “lines” of therapy. The most active agents tend to be platinum agents, fluoropyrimidines, and taxanes. However, fitness for chemotherapy, response rates, and progression-free survival drops from one line to the next due to disease progression and side effects of previous treatment.
Angiogenesis plays an important role in gastric cancer growth and spread, and high...
Compliance with Ethical Standards
Conflict of Interest
The authors declare that they have no conflict of interest.
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
For this type of study, formal consent is not required.
- 4.Ohtsu A, Shah MA, Van Cutsem E, Rha SY, Sawaki A, Park SR, et al. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study. J Clin Oncol Off J Am Soc Clin Oncol. 2011;29:3968–76. https://doi.org/10.1200/JCO.2011.36.2236.CrossRefGoogle Scholar
- 5.Shen L, Li J, Xu J, Pan H, Dai G, Qin S, et al. Bevacizumab plus capecitabine and cisplatin in Chinese patients with inoperable locally advanced or metastatic gastric or gastroesophageal junction cancer: randomized, double-blind, phase III study (AVATAR study). Gastric Cancer. 2015;18:168–76. https://doi.org/10.1007/s10120-014-0351-5.CrossRefPubMedGoogle Scholar
- 6.Fuchs CS, Tomasek J, Yong CJ, Dumitru F, Passalacqua R, Goswami C, et al. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2014;383:31–9. https://doi.org/10.1016/S0140-6736(13)61719-5.CrossRefGoogle Scholar
- 7.Wilke H, Muro K, Van Cutsem E, Oh S-C, Bodoky G, Shimada Y, et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol. 2014;15:1224–35. https://doi.org/10.1016/S1470-2045(14)70420-6.CrossRefPubMedPubMedCentralGoogle Scholar
- 11.Escudier B, Porta C, Bono P, Powles T, Eisen T, Sternberg CN, et al. Randomized, controlled, double-blind, cross-over trial assessing treatment preference for pazopanib versus sunitinib in patients with metastatic renal cell carcinoma: PISCES Study. J Clin Oncol Off J Am Soc Clin Oncol. 2014;32:1412–8. https://doi.org/10.1200/JCO.2013.50.8267.CrossRefGoogle Scholar
- 12.Kim ST, Lee J, Lee SJ, Park SH, Jung S-H, Park YS, et al. Prospective phase II trial of pazopanib plus CapeOX (capecitabine and oxaliplatin) in previously untreated patients with advanced gastric cancer. Oncotarget. 2016;7:24088–96. https://doi.org/10.18632/oncotarget.8175.CrossRefPubMedPubMedCentralGoogle Scholar
- 13.Burris HA, Dowlati A, Moss RA, Infante JR, Jones SF, Spigel DR, et al. Phase I study of pazopanib in combination with paclitaxel and carboplatin given every 21 days in patients with advanced solid tumors. Mol Cancer Ther. 2012;11:1820–8. https://doi.org/10.1158/1535-7163.MCT-11-0997.CrossRefPubMedGoogle Scholar
- 17.Oza AM, Cook AD, Pfisterer J, Embleton A, Ledermann JA, Pujade-Lauraine E, et al. Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial. Lancet Oncol. 2015;16:928–36. https://doi.org/10.1016/S1470-2045(15)00086-8.CrossRefPubMedPubMedCentralGoogle Scholar
- 19.Lopez-Chavez A, Young T, Fages S, Leon L, Schiller JH, Dowlati A, et al. Bevacizumab maintenance in patients with advanced non-small-cell lung cancer, clinical patterns, and outcomes in the Eastern Cooperative Oncology Group 4599 Study: results of an exploratory analysis. J Thorac Oncol. 2012;7:1707–12. https://doi.org/10.1097/JTO.0b013e318265b500.CrossRefPubMedGoogle Scholar
- 20.Yu P, Huang L, Cheng G, Yang L, Dai G, Ying J, et al. Treatment strategy and prognostic factors for Krukenberg tumors of gastric origin: report of a 10-year single-center experience from China. Oncotarget. 2017;8:82558–70. https://doi.org/10.18632/oncotarget.19759.CrossRefPubMedPubMedCentralGoogle Scholar
- 21.Kim ST, Jang H-L, Lee SJ, Lee J, Choi Y-L, Kim K-M, et al. Pazopanib, a novel multitargeted kinase inhibitor, shows potent in vitro antitumor activity in gastric cancer cell lines with FGFR2 amplification. Mol Cancer Ther. 2014;13:2527–36. https://doi.org/10.1158/1535-7163.MCT-14-0255.CrossRefPubMedGoogle Scholar